Hims & Hers (HIMS.US) is up more than 6% in pre-market trading today following news of its planned acquisition of the European platform, ZAVA. The acquisition is part of the company's strategy to expand its global operations.
The exact terms of the transaction are not yet known, but according to press reports, the deal will be an all-cash transaction and is expected to close in 2026. For the company, this presents an opportunity to expand operations in the UK, Germany, France, and Ireland.
The company has seen an impressive over 130% increase since the end of April, when the cooperation between Hims & Hers and Novo Nordisk for the distribution of Wegovy was announced. Hims' strongest revenue growth driver has been the sale of cheaper copycats of the weight-loss drugs, thanks to Novo Nordisk and Eli Lilly products being listed on drug shortage lists. When these drugs were removed from the list, the sale of copycats ceased to be legal, and the company's stock plummeted by over 62% from its February highs at its worst point. Currently, the company's stock has returned to around its February levels.
The company's stock is up over 6% in pre-market trading. Source: xStation
Daily summary: Silver plunges 9% ๐จIndices, crypto and precious metals under pressure
Does the current sell-off signal the end of quantum companies?
Howmet Aerospace surges 10% after earnings reaching $100 bilion market cap ๐
US Open: Cisco Systems slides 10% after earnings ๐ Mixed sentiments on Wall Street
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
